RHAG and lung carcinoma: Studies show that Rh2 can inhibit melanoma (Wang et al., 2017), glioma (Kim et al., 2007), liver cancer (Yang et al., 2016), breast cancer (Zare-Zardini et al., 2018), and lung cancer (An et al., 2013).